Reply to Dr. Vadhithala’s Letter to the Editor re: Marc A. Furrer, Benjamin Lyttwin, Michael S. Pärli, et al. Incidental Prostate Cancer Is an Uncommon but Clinically Non-negligible Cause of Death in Selected Long-term Survivors of Urothelial Carcinoma—Oncological Outcomes and a Proposed Follow-up Strategy from a Tertiary Referral Center. Eur Urol Open Sci 2026;86:10–9 Authors: Marc A Furrer, Patrick Y Wuethrich, Niall M Corcoran Published: 2026 Dear Editor, We would like to thank the authors for their thoughtful and well-structured reflections addressing our recently published study [1] and for providing the opportunity to further clarify the issues raised in their comment. Their appraisal is balanced and constructive, and it highlights several methodological and interpretative aspects that are important for the broader understanding of incidental prostate cancer in the setting of radical cystoprostatectomy. We welcome this engagement, as it contributes meaningfully to ongoing discussions in this evolving field. The points raised regarding the statistical stability of effect estimates in the context of a limited number of prostate cancer–specific events are well taken. As correctly outlined, analyses based on sparse-event data may affect both the magnitude and precision of hazard ratio estimates, potentially leading to wide confidence intervals and reduced statistical certainty. Importantly, this limitation was explicitly acknowledged in the original manuscript, where all reported associations were clearly framed as exploratory and interpreted with appropriate caution. In this context, the comment largely reinforces considerations already discussed, while appropriately emphasizing that the interpretation of such findings should prioritize the direction, consistency, and clinical plausibility of observed associations rather than their absolute numerical values alone. The discussion on biochemical recurrence and its relationship with clinically meaningful disease progression provides an additional and valuable perspective. As highlighted by the authors, incidental prostate cancer identified in cystoprostatectomy specimens may differ biologically from primary prostate cancer diagnosed and treated in other clinical contexts. This distinction is central to the conceptual framework of our study, which emphasized disease heterogeneity and supported a conservative, risk-adapted surveillance strategy. Although the suggestion to incorporate molecular or genomic markers is certainly of scientific interest and may refine future risk stratification, it extends beyond the scope of this analysis and represents an important avenue for future research, rather than a prerequisite for interpreting the findings of this analysis. The comment also raises the issue of temporal heterogeneity across the extended study period. We agree that changes in imaging modalities, staging techniques, and pathological classification over time may influence detection patterns and staging accuracy. These factors are inherent to long-term observational studies and were acknowledged as such in the original manuscript. However, they are unlikely to materially impact the primary endpoint of prostate cancer–specific mortality, which remains a robust and clinically meaningful outcome. At the same time, the prolonged duration of follow-up represents a key strength of the study, allowing for the capture of late events and providing insights into long-term disease behavior that are not readily achievable in shorter series. Overall, this comment offers a valuable perspective on the interpretation of long-term outcomes in incidental prostate cancer and helps to further contextualize our findings within the broader methodological and clinical landscape. Though several of the points raised reiterate considerations already addressed, they underscore the importance of cautious interpretation, individualized clinical decision-making, and continued research in this area. Importantly, the central conclusions of our study—that incidental prostate cancer is predominantly indolent but may have clinical relevance in a small subset of long-term survivors—remain well supported by the data presented. Conflicts of interest: The authors have nothing to disclose. References